MARKET

TENX

TENX

Tenax Therapeutics Inc
NASDAQ
3.343
-0.057
-1.67%
After Hours: 3.350 +0.007 +0.20% 18:03 07/12 EDT
OPEN
3.354
PREV CLOSE
3.400
HIGH
3.491
LOW
3.340
VOLUME
5.51K
TURNOVER
0
52 WEEK HIGH
61.20
52 WEEK LOW
2.770
MARKET CAP
6.55M
P/E (TTM)
-0.1363
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at TENX last week (0701-0705)?
Weekly Report · 6d ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Qualigen Therapeutics (NASDAQ:QLGN) shares moved upwards by 42.5% to $0.25 during Thursday's regular session. Akso Health Group stock rose 11.68% and Sharps Technology stock rose 33.56% during the session.
Benzinga · 07/04 16:31
Weekly Report: what happened at TENX last week (0624-0628)?
Weekly Report · 07/01 09:35
Weekly Report: what happened at TENX last week (0617-0621)?
Weekly Report · 06/24 09:37
Weekly Report: what happened at TENX last week (0610-0614)?
Weekly Report · 06/17 09:34
Tenax Therapeutics Enhances Incentives and Adjusts Leadership Structure
TipRanks · 06/13 21:15
Weekly Report: what happened at TENX last week (0603-0607)?
Weekly Report · 06/10 09:35
Weekly Report: what happened at TENX last week (0527-0531)?
Weekly Report · 06/03 09:36
More
About TENX
Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 (IV), TNX-102 (subcutaneous) and TNX-103 (oral) levosimendan. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF).

Webull offers Tenax Therapeutics Inc stock information, including NASDAQ: TENX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TENX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TENX stock methods without spending real money on the virtual paper trading platform.